Medical Filtration - Company Evaluation Report, 2025 (Abridged Report)
Description
The Medical filtration Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for Medical filtration. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and emerging trends shaping the industry. MarketsandMarkets 360 Quadrants evaluated over 40 companies of which the Top 15 Medical filtration Companies were categorized and recognized as the quadrant leaders.
Medical filtration is crucial for removing contaminants from fluids, including liquids and gases, to ensure safety and purity in medical applications. This market encompasses various filtration techniques, such as microfiltration, ultrafiltration, and nanofiltration, which are vital for infection control and patient safety. The increasing prevalence of chronic diseases and stringent regulatory standards are driving demand for advanced filtration solutions, fueling the market's growth. As a key component in preserving product integrity, medical filtration plays a vital role in the healthcare industry.
Medical filtration is widely used in healthcare applications such as dialysis, drug delivery, IV infusion, sterile filtration, endoscopy, sterile processing, and bio-artificial processes, ensuring patient safety and treatment effectiveness. These applications rely on advanced filter materials, including polyethersulfone (PES), polysulfone (PSU), polyvinylidene fluoride (PVDF), polytetrafluoroethylene (PTFE), and polypropylene (PP), which provide excellent chemical resistance, biocompatibility, and filtration efficiency. Various filtration technologies, including ultrafiltration (UF), microfiltration (MF), nanofiltration (NF), reverse osmosis (RO), and gas filtration, help eliminate contaminants, bacteria, viruses, and particulates while maintaining the purity of medical fluids and devices. By integrating these filtration solutions, healthcare systems can enhance sterility, optimize fluid purity, and improve overall patient outcomes.
The 360 Quadrant maps the Medical filtration companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the Medical filtration quadrant. The top criteria for product footprint evaluation included By Material (Polyethersulfone (PES), Polytetrafluoroethylene (PTFE), Polypropylene (PP), Polyvinylidene Fluoride (PVDF), and other materials), By Process Technology (Microfiltration, Ultrafiltration, Nanofiltration, Reverse osmosis , Gas filtration, and others), By Design (Systems (RTU units), filtration modules (consumables), and other process/design filtration solutions), End-User and Application.
Key Players:
Merck KGaA (Germany), 3M (Solventum) (US), Danaher (US), Sartorius AG (Germany), Asahi Kasei Corporation (Japan), Baxter (US), Veolia (France), Thermo Fisher Scientific Inc (US), Donaldson Company Inc (US), PARKER HANNIFIN CORP (US), Entegris (US), and MANN+HUMMEL (Germany) are some of the major players in this market. These companies have adopted strategies, such as investments & expansions, product launches, partnerships, agreements, and acquisitions, to maintain their positions in the market.
Merck KGaA
Merck KGaA holds a significant position in the medical filtration market, known for its diverse Company Product Portfolio and robust Company Market Share. Based in Germany, the company excels in multiple segments, including Healthcare and Life Sciences, with the Process Solutions unit contributing significantly to its success. Merck's continuous investments, such as expansions in Cork, Ireland, denote its commitment to scaling production capabilities for novel therapies and diagnostics.
3M
3M has strategically positioned itself through initiatives like the spin-off of its healthcare business, forming Solventum Corporation. This move boosted its focus on medical filtration, enhancing its Company Positioning and Market Share. Known for its Zeta Plus filters, 3M remains a frontrunner in offering scalable, high-efficiency filtration solutions.
Danaher
Danaher's competitive edge is fortified through strategic mergers, showcasing strong Company Analysis and Positioning across its comprehensive Company Product Portfolio. The merger of Cytiva and Pall’s life sciences into its operations has enriched Danaher's capacity to deliver biotechnology solutions, marking its presence as a versatile supplier in the market.
Medical filtration is crucial for removing contaminants from fluids, including liquids and gases, to ensure safety and purity in medical applications. This market encompasses various filtration techniques, such as microfiltration, ultrafiltration, and nanofiltration, which are vital for infection control and patient safety. The increasing prevalence of chronic diseases and stringent regulatory standards are driving demand for advanced filtration solutions, fueling the market's growth. As a key component in preserving product integrity, medical filtration plays a vital role in the healthcare industry.
Medical filtration is widely used in healthcare applications such as dialysis, drug delivery, IV infusion, sterile filtration, endoscopy, sterile processing, and bio-artificial processes, ensuring patient safety and treatment effectiveness. These applications rely on advanced filter materials, including polyethersulfone (PES), polysulfone (PSU), polyvinylidene fluoride (PVDF), polytetrafluoroethylene (PTFE), and polypropylene (PP), which provide excellent chemical resistance, biocompatibility, and filtration efficiency. Various filtration technologies, including ultrafiltration (UF), microfiltration (MF), nanofiltration (NF), reverse osmosis (RO), and gas filtration, help eliminate contaminants, bacteria, viruses, and particulates while maintaining the purity of medical fluids and devices. By integrating these filtration solutions, healthcare systems can enhance sterility, optimize fluid purity, and improve overall patient outcomes.
The 360 Quadrant maps the Medical filtration companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the Medical filtration quadrant. The top criteria for product footprint evaluation included By Material (Polyethersulfone (PES), Polytetrafluoroethylene (PTFE), Polypropylene (PP), Polyvinylidene Fluoride (PVDF), and other materials), By Process Technology (Microfiltration, Ultrafiltration, Nanofiltration, Reverse osmosis , Gas filtration, and others), By Design (Systems (RTU units), filtration modules (consumables), and other process/design filtration solutions), End-User and Application.
Key Players:
Merck KGaA (Germany), 3M (Solventum) (US), Danaher (US), Sartorius AG (Germany), Asahi Kasei Corporation (Japan), Baxter (US), Veolia (France), Thermo Fisher Scientific Inc (US), Donaldson Company Inc (US), PARKER HANNIFIN CORP (US), Entegris (US), and MANN+HUMMEL (Germany) are some of the major players in this market. These companies have adopted strategies, such as investments & expansions, product launches, partnerships, agreements, and acquisitions, to maintain their positions in the market.
Merck KGaA
Merck KGaA holds a significant position in the medical filtration market, known for its diverse Company Product Portfolio and robust Company Market Share. Based in Germany, the company excels in multiple segments, including Healthcare and Life Sciences, with the Process Solutions unit contributing significantly to its success. Merck's continuous investments, such as expansions in Cork, Ireland, denote its commitment to scaling production capabilities for novel therapies and diagnostics.
3M
3M has strategically positioned itself through initiatives like the spin-off of its healthcare business, forming Solventum Corporation. This move boosted its focus on medical filtration, enhancing its Company Positioning and Market Share. Known for its Zeta Plus filters, 3M remains a frontrunner in offering scalable, high-efficiency filtration solutions.
Danaher
Danaher's competitive edge is fortified through strategic mergers, showcasing strong Company Analysis and Positioning across its comprehensive Company Product Portfolio. The merger of Cytiva and Pall’s life sciences into its operations has enriched Danaher's capacity to deliver biotechnology solutions, marking its presence as a versatile supplier in the market.
Table of Contents
191 Pages
- 1 Introduction
- 1.1 Market Definition
- 1.2 Inclusions & Exclusions
- 1.3 Stakeholders
- 2 Executive Summary
- 3 Market Overview
- 3.1 Introduction
- 3.2 Market Dynamics
- 3.2.1 Drivers
- 3.2.1.1 Increasing Demand For Advanced Healthcare Solutions
- 3.2.1.2 Rising Awareness Of Infection Control
- 3.2.1.3 Technological Advancements
- 3.2.2 Restraints
- 3.2.2.1 High Capital Investments
- 3.2.2.2 Stringent Regulatory Compliance
- 3.2.3 Opportunities
- 3.2.3.1 Growing Healthcare Investments In Emerging Economies
- 3.2.3.2 Adoption Of Single-use Technologies
- 3.2.4 Challenges
- 3.2.4.1 Speed And Yield Issues
- 3.3 Porter’s Five Forces Analysis
- 3.3.1 Threat Of New Entrants
- 3.3.2 Threat Of Substitutes
- 3.3.3 Bargaining Power Of Suppliers
- 3.3.4 Bargaining Power Of Buyers
- 3.3.5 Intensity Of Competitive Rivalry
- 3.4 Impact Of Ai/Gen Ai
- 3.5 Value Chain Analysis
- 3.5.1 Raw Material Suppliers
- 3.5.2 Manufacturers
- 3.5.3 Distributors
- 3.5.4 End Users
- 3.6 Ecosystem Analysis
- 3.7 Technology Analysis
- 3.7.1 Key Technologies
- 3.7.1.1 Microfiltration
- 3.7.1.2 Ultrafiltration
- 3.7.1.3 Nanofiltration
- 3.7.2 Complementary Technologies
- 3.7.2.1 Single-use Technology
- 3.7.3 Adjacent Technologies
- 3.7.3.1 Chromatography
- 3.8 Trends/Disruptions Impacting Customer Business
- 3.9 Key Conferences And Events, 2025–2026
- 3.10 Patent Analysis
- 3.10.1 Introduction
- 3.10.2 Legal Status Of Patents
- 3.10.3 Jurisdiction Analysis
- 4 Competitive Landscape
- 4.1 Overview
- 4.2 Key Player Strategies/Right To Win
- 4.3 Revenue Analysis, 2021–2023
- 4.4 Market Share Analysis, 2023
- 4.5 Company Valuation And Financial Metrics
- 4.6 Product Comparison
- 4.7 Company Evaluation Matrix: Key Players, 2023
- 4.7.1 Stars
- 4.7.2 Emerging Leaders
- 4.7.3 Pervasive Players
- 4.7.4 Participants
- 4.7.5 Company Footprint: Key Players, 2023
- 4.7.5.1 Region Footprint
- 4.7.5.2 Material Footprint
- 4.7.5.3 Process Technology Footprint
- 4.7.5.4 Design/Process Footprint
- 4.7.5.5 Application Footprint
- 4.7.5.6 End User Footprint
- 4.8 Company Evaluation Matrix: Startups/Smes, 2023
- 4.8.1 Progressive Companies
- 4.8.2 Responsive Companies
- 4.8.3 Dynamic Companies
- 4.8.4 Starting Blocks
- 4.8.5 Competitive Benchmarking: Startups/Smes, 2023
- 4.8.5.1 Detailed List Of Key Startups/Smes
- 4.8.5.2 Competitive Benchmarking Of Key Startups/Smes
- 4.9 Competitive Scenario
- 4.9.1 Product Launches
- 4.9.2 Deals
- 4.9.3 Expansions
- 4.9.4 Other Developments
- 5 Company Profiles – Medical Filtration Equipment Providers
- 5.1 Key Players
- 5.1.1 Merck Kgaa
- 5.1.1.1 Business Overview
- 5.1.1.2 Products/Solutions/Services Offered
- 5.1.1.3 Recent Developments
- 5.1.1.3.1 Expansions
- 5.1.1.4 Mnm View
- 5.1.1.4.1 Right To Win
- 5.1.1.4.2 Strategic Choices
- 5.1.1.4.3 Weaknesses And Competitive Threats
- 5.1.2 3m (Solventum)
- 5.1.2.1 Business Overview
- 5.1.2.2 Products/Solutions/Services Offered
- 5.1.2.3 Recent Developments
- 5.1.2.3.1 Other Developments
- 5.1.2.4 Mnm View
- 5.1.2.4.1 Right To Win
- 5.1.2.4.2 Strategic Choices
- 5.1.2.4.3 Weaknesses And Competitive Threats
- 5.1.3 Danaher
- 5.1.3.1 Business Overview
- 5.1.3.2 Products/Solutions/Services Offered
- 5.1.3.3 Recent Developments
- 5.1.3.3.1 Deals
- 5.1.3.3.2 Other Developments
- 5.1.3.4 Mnm View
- 5.1.3.4.1 Right To Win
- 5.1.3.4.2 Strategic Choices
- 5.1.3.4.3 Weaknesses And Competitive Threats
- 5.1.4 Sartorius Ag
- 5.1.4.1 Business Overview
- 5.1.4.2 Products/Solutions/Services Offered
- 5.1.4.3 Recent Developments
- 5.1.4.3.1 Product Launches
- 5.1.4.4 Mnm View
- 5.1.4.4.1 Right To Win
- 5.1.4.4.2 Strategic Choices
- 5.1.4.4.3 Weaknesses And Competitive Threats
- 5.1.5 Asahi Kasei Corporation
- 5.1.5.1 Business Overview
- 5.1.5.2 Products/Solutions/Services Offered
- 5.1.5.3 Mnm View
- 5.1.5.3.1 Right To Win
- 5.1.5.3.2 Strategic Choices
- 5.1.5.3.3 Weaknesses And Competitive Threats
- 5.1.6 Baxter
- 5.1.6.1 Business Overview
- 5.1.6.2 Products/Solutions/Services Offered
- 5.1.6.3 Recent Developments
- 5.1.6.3.1 Deals
- 5.1.6.4 Mnm View
- 5.1.6.4.1 Right To Win
- 5.1.6.4.2 Strategic Choices
- 5.1.6.4.3 Weaknesses And Competitive Threats
- 5.1.7 Thermo Fisher Scientific Inc.
- 5.1.7.1 Business Overview
- 5.1.7.2 Products/Solutions/Services Offered
- 5.1.7.3 Mnm View
- 5.1.8 Veolia
- 5.1.8.1 Business Overview
- 5.1.8.2 Products/Solutions/Services Offered
- 5.1.8.3 Recent Developments
- 5.1.8.3.1 Product Launches
- 5.1.8.4 Mnm View
- 5.1.8.4.1 Right To Win
- 5.1.8.4.2 Strategic Choices
- 5.1.8.4.3 Weaknesses And Competitive Threats
- 5.1.9 Donaldson Company, Inc.
- 5.1.9.1 Business Overview
- 5.1.9.2 Products/Solutions/Services Offered
- 5.1.9.3 Recent Developments
- 5.1.9.3.1 Expansions
- 5.1.9.4 Mnm View
- 5.1.10 Parker Hannifin Corp
- 5.1.10.1 Business Overview
- 5.1.10.2 Products/Solutions/Services Offered
- 5.1.10.3 Mnm View
- 5.1.11 Entegris
- 5.1.11.1 Business Overview
- 5.1.11.2 Products/Solutions/Services Offered
- 5.1.11.3 Mnm View
- 5.1.12 Mann+Hummel
- 5.1.12.1 Business Overview
- 5.1.12.2 Products/Solutions/Services Offered
- 5.1.12.3 Mnm View
- 5.2 Other Players
- 5.2.1 Corning Incorporated
- 5.2.2 Critical Process Filtration, Inc.
- 5.2.3 Cobetter
- 5.2.4 Graver Technologies
- 5.2.5 Ertelalsop
- 5.2.6 Kasag Swiss Ag
- 5.2.7 Filtrox Ag
- 5.2.8 Membrane Solutions
- 5.2.9 Cole-parmer Instrument Company, Llc
- 5.2.10 Meissner Filtration Products, Inc.
- 5.2.11 Medical Filtration Solutions Ltd.
- 5.2.12 Sefar Ag
- 5.2.13 Walker Filtration
- 5.2.14 Saint-gobain
- 6 Company Profiles - Automated Endoscope Reprocessor Providers
- 6.1 Key Players
- 6.1.1 Steris
- 6.1.1.1 Business Overview
- 6.1.1.2 Products/Solutions/Services Offered
- 6.1.1.3 Recent Developments
- 6.1.1.3.1 Deals
- 6.1.1.4 Mnm View
- 6.1.1.4.1 Right To Win
- 6.1.1.4.2 Strategic Choices
- 6.1.1.4.3 Weaknesses And Competitive Threats
- 6.1.2 Fortive
- 6.1.2.1 Business Overview
- 6.1.2.2 Products/Solutions/Services Offered
- 6.1.2.3 Recent Developments
- 6.1.2.3.1 Deals
- 6.1.2.4 Mnm View
- 6.1.2.4.1 Right To Win
- 6.1.2.4.2 Strategic Choices
- 6.1.2.4.3 Weaknesses And Competitive Threats
- 6.1.3 Olympus Corporation
- 6.1.3.1 Business Overview
- 6.1.3.2 Products/Solutions/Services Offered
- 6.1.3.3 Recent Developments
- 6.1.3.3.1 Product Launches
- 6.1.3.4 Mnm View
- 6.1.3.4.1 Right To Win
- 6.1.3.4.2 Strategic Choices
- 6.1.3.4.3 Weaknesses And Competitive Threats
- 6.1.4 Ecolab
- 6.1.4.1 Business Overview
- 6.1.4.2 Products/Solutions/Services Offered
- 6.1.4.3 Recent Developments
- 6.1.4.3.1 Product Launches
- 6.1.4.4 Mnm View
- 6.1.4.4.1 Right To Win
- 6.1.4.4.2 Strategic Choices
- 6.1.4.4.3 Weaknesses And Competitive Threats
- 6.1.5 Getinge
- 6.1.5.1 Business Overview
- 6.1.5.2 Products/Solutions/Services Offered
- 6.1.5.3 Recent Developments
- 6.1.5.3.1 Expansions
- 6.1.5.4 Mnm View
- 6.1.5.4.1 Right To Win
- 6.1.5.4.2 Strategic Choices
- 6.1.5.4.3 Weaknesses And Competitive Threats
- 6.1.6 Steelcobelimed (Metall Zug Group)
- 6.1.6.1 Business Overview
- 6.1.6.2 Products/Solutions/Services Offered
- 6.1.6.3 Recent Developments
- 6.1.6.3.1 Deals
- 6.1.6.4 Mnm View
- 6.1.7 Endo-technik W. Griesat (Creo)
- 6.1.7.1 Business Overview
- 6.1.7.2 Products/Solutions/Services Offered
- 6.1.7.3 Mnm View
- 6.1.8 Wassenburg Medical B.V. (Hoya Corporation)
- 6.1.8.1 Business Overview
- 6.1.8.2 Products/Solutions/Services Offered
- 6.1.8.3 Recent Developments
- 6.1.8.3.1 Deals
- 7 Company Profiles – Dialysis Equipment Providers
- 7.1 Key Players
- 7.1.1 Fresenius Medical Care Ag
- 7.1.1.1 Business Overview
- 7.1.1.2 Products/Solutions/Services Offered
- 7.1.1.3 Recent Developments
- 7.1.1.3.1 Product Launches
- 7.1.1.3.2 Deals
- 7.1.1.4 Mnm View
- 7.1.1.4.1 Right To Win
- 7.1.1.4.2 Strategic Choices
- 7.1.1.4.3 Weaknesses And Competitive Threats
- 7.1.2 Baxter
- 7.1.2.1 Business Overview
- 7.1.2.2 Products/Solutions/Services Offered
- 7.1.2.3 Recent Developments
- 7.1.2.3.1 Deals
- 7.1.2.4 Mnm View
- 7.1.2.4.1 Right To Win
- 7.1.2.4.2 Strategic Choices
- 7.1.2.4.3 Weaknesses And Competitive Threats
- 7.1.3 Davita Inc.
- 7.1.3.1 Business Overview
- 7.1.3.2 Products/Solutions/Services Offered
- 7.1.3.3 Recent Developments
- 7.1.3.3.1 Deals
- 7.1.3.3.2 Expansions
- 7.1.3.4 Mnm View
- 7.1.3.4.1 Right To Win
- 7.1.3.4.2 Strategic Choices
- 7.1.3.4.3 Weaknesses And Competitive Threats
- 7.1.4 Nikkiso Co., Ltd.
- 7.1.4.1 Business Overview
- 7.1.4.2 Products/Solutions/Services Offered
- 7.1.4.3 Recent Developments
- 7.1.4.3.1 Deals
- 7.1.4.4 Mnm View
- 7.1.4.4.1 Right To Win
- 7.1.4.4.2 Strategic Choices
- 7.1.4.4.3 Weaknesses And Competitive Threats
- 7.1.5 B. Braun Se
- 7.1.5.1 Business Overview
- 7.1.5.2 Products/Solutions/Services Offered
- 7.1.5.3 Recent Developments
- 7.1.5.3.1 Product Launches
- 7.1.5.3.2 Expansions
- 7.1.5.4 Mnm View
- 7.1.5.4.1 Right To Win
- 7.1.5.4.2 Strategic Choices
- 7.1.5.4.3 Weaknesses And Competitive Threats
- 7.1.6 Nipro
- 7.1.6.1 Business Overview
- 7.1.6.2 Products/Solutions/Services Offered
- 7.1.6.3 Recent Developments
- 7.1.6.3.1 Product Launches
- 7.1.7 Toray Medical Co., Ltd.
- 7.1.7.1 Business Overview
- 7.1.7.2 Products/Solutions/Services Offered
- 7.1.8 Medionics
- 7.1.8.1 Business Overview
- 7.1.8.2 Products/Solutions/Services Offered
- 8 Appendix
- 8.1 Research Methodology
- 8.1.1 Research Data
- 8.1.1.1 Secondary Data
- 8.1.1.2 Primary Data
- 8.1.2 Research Assumptions
- 8.1.3 Research Limitations And Risk Analysis
- 8.2 Company Evaluation Matrix: Methodology
- 8.3 Author Details
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
